Ambry CARE Program Enhances Breast Cancer Risk Assessments with Integrated Breast Density—Directly in EHR
Integrating Breast Density Yields More Precise Risk Scores at the Point of Care
Tempus AI (NASDAQ:TEM) subsidiary Ambry Genetics has announced a pivotal enhancement to its Ambry CARE Program, the company’s digital platform streamlining cancer risk assessment and genetic testing workflows. The update brings breast density into the Tyrer-Cuzick (TC) scoring model directly within electronic health records (EHR), equipping clinicians with highly personalized risk estimates—without leaving their clinical workflow.
This upgrade addresses a substantial gap in patient care: despite breast cancer being the most common cancer among women, 93% of women with elevated risk and eligibility for breast MRI never receive one. By embedding the upgraded TC risk model into EHR, Ambry enables actionable, individualized guidance on screening and prevention—right where critical decisions are made.
What Sets This Update Apart? More Personalized Assessments and Workflow Integration
The Tyrer-Cuzick (TC) model is among the most widely cited risk assessment tools, guiding clinical screening decisions in line with recommendations from bodies like the American College of Radiology (ACR). Accuracy in these models is tied to the number and type of incorporated risk factors, with breast density recognized as a major variable. CARE’s new feature offers clinicians four TC score options matched to the BI-RADS breast density categories (A-D), giving providers the flexibility to choose the best risk profile for each patient.
CARE not only improves clinical utility, but it also ensures compliance with FDA breast density reporting mandates—by embedding breast density directly into patient risk assessments instead of as a standalone compliance item.
Key Takeaways: Increased Accuracy and Expanded Access to Risk Evaluation
| Feature | Clinical Value |
|---|---|
| Integrated Tyrer-Cuzick scoring with breast density | Offers precise, individualized breast cancer risk scores at the point of care |
| Alignment with BI-RADS breast density (A–D) | Lets clinicians choose the risk estimate best tailored to each patient |
| EHR workflow integration | Delivers results without disrupting existing clinical processes |
| 99.5% NCCN Guideline Interpretation Accuracy | Proven reliable for hereditary cancer risk evaluation and screening recommendations |
| Guidance for Elevated Risk Patients (=20%) | Helps identify candidates for intensive screening, like annual breast MRI |
Actionable Insight at the Point of Care Improves Outcomes
Experts underscore the impact of embedding TC scores and breast density directly into the EHR. “Calculating a Tyrer-Cuzick score and engaging women in discussions about their breast cancer risk, screening, and risk-reduction strategies can be lifesaving,” said Dr. Melissa Frey of New York’s Division of Gynecologic Oncology. Ambry CARE, she notes, “makes the assessment even more powerful, as breast density is a significant factor in understanding an individual’s risk.”
Ambry CEO Tom Schoenherr echoes this, emphasizing that actionable insights must meet providers in their workflow to make a real difference in patient care.
Looking Ahead: Digital Risk Tools Supporting More Personalized Care
Ambry’s update exemplifies the convergence of precision medicine, digital workflow integration, and compliance. With validated 99.5% accuracy in NCCN guideline interpretation, the CARE Program stands out as a robust digital risk assessment solution—helping clinicians identify women at elevated risk for breast cancer so they can intervene sooner and more effectively.
For more information on the CARE Program, visit ambrygen.com/care.
Summary Table: How the New CARE Integration Supports Clinicians
| Integration Element | Clinical Benefit |
|---|---|
| Breast density in TC score | Elevates accuracy in identifying women who qualify for advanced screening |
| EHR embedding | Saves time and streamlines decision-making at the point of care |
| FDA and NCCN alignment | Facilitates compliance while supporting best clinical practice |
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI